The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
 
Arnaud Scherpereel
No Relationships to Disclose
 
Julien Mazieres
Research Funding - Bristol-Myers Squibb; Roche (Inst)
 
Laurent Greillier
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Pfizer
 
Pascal Dô
No Relationships to Disclose
 
Olivier Bylicki
Consulting or Advisory Role - MSD Oncology
 
Isabelle Monnet
Research Funding - Astellas Oncology; AZD; MSD
Travel, Accommodations, Expenses - MSD; Novartis
 
Romain Corre
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Roche
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Roche
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sysmex
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Myriam Locatelli-Sanchez
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pierre Fabre
 
Olivier Molinier
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
 
Luc Thiberville
No Relationships to Disclose
 
Thierry Urban
No Relationships to Disclose
 
Catherine Ligeza-poisson
No Relationships to Disclose
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Elodie Amour
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Denis Moro-Sibilot
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Roche (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche